APA (7th ed.) Citation

Taha, H. F., Elsayed, D. H., Salem, R., Mandour, D., Bayomy, M., Rashed, H., . . . Elfarargy, O. M. (2022). Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score. Contemporary Oncology / Współczesna Onkologia, 26(3), 196. https://doi.org/10.5114/wo.2022.120592

Chicago Style (17th ed.) Citation

Taha, Heba F., Dalia Hamouda Elsayed, Reham Salem, Doaa Mandour, Mohammed Bayomy, Hayam Rashed, Mostafa Kamel, Mohamed Elderey, and Ola M. Elfarargy. "Outcome of Docetaxel in Treatment of Metastatic Hormone-sensitive Prostate Cancer and Correlation with Hemoglobin, Albumin, Lymphocyte and Platelets Score." Contemporary Oncology / Współczesna Onkologia 26, no. 3 (2022): 196. https://doi.org/10.5114/wo.2022.120592.

MLA (9th ed.) Citation

Taha, Heba F., et al. "Outcome of Docetaxel in Treatment of Metastatic Hormone-sensitive Prostate Cancer and Correlation with Hemoglobin, Albumin, Lymphocyte and Platelets Score." Contemporary Oncology / Współczesna Onkologia, vol. 26, no. 3, 2022, p. 196, https://doi.org/10.5114/wo.2022.120592.